Jazz Pharmaceuticals (JAZZ) EBITDA (2010 - 2026)

Jazz Pharmaceuticals has reported EBITDA for 17 years, with the latest figure at $336.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 384.21% year-over-year to $336.6 million; the trailing twelve-month figure through Mar 2026 stood at -$37.7 million (down 105.24% YoY), and the FY2025 full-year result was -$430.2 million, down 160.04% from the prior year.
• EBITDA for Q1 2026 stood at $336.6 million, up from $254.5 million in the prior quarter.
• The five-year high for EBITDA was $336.6 million in Q1 2026, with the low at -$686.4 million in Q2 2025.
• Average EBITDA over 5 years is $67.1 million, with a median of $122.5 million recorded in 2023.
• Year-over-year, EBITDA plunged 633.39% in 2022 and soared 596.17% in 2023.
• Tracing JAZZ's EBITDA over 5 years: stood at -$263.4 million in 2022, then soared by 146.51% to $122.5 million in 2023, then jumped by 55.73% to $190.8 million in 2024, then surged by 33.43% to $254.5 million in 2025, then soared by 32.24% to $336.6 million in 2026.
• The last three EBITDA figures came in at $336.6 million (Q1 2026), $254.5 million (Q4 2025), and $57.5 million (Q3 2025), per Business Quant data.

Peer Comparison